This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: AZN's Q4 Earnings, FDA Approval for LLY & SNY's Drugs
by Kinjel Shah
AstraZeneca (AZN) announces Q4 results. FDA approves Lilly's COVID-19 antibody cocktail & Sanofi's (SNY) Libtayo for a new indication.
Biotech Stock Roundup: Q4 Results of BMY, REGN, BIIB & Other Regulatory Updates
by Zacks Equity Research
Earnings of leading biotechs like Biogen (BIIB), Gilead (GILD) and Regeneron (REGN) dominate last week's headlines in the biotech sector.
Sanofi (SNY)/Regeneron's Libtayo Gets FDA Nod for 2nd Indication
by Zacks Equity Research
The FDA approves Sanofi (SNY)/Regeneron's Libtayo for treating patients with advanced/metastatic basal cell carcinoma. The is the second approved indication for the drug in the United States.
Regeneron (REGN) Q4 Earnings, Sales Beat on Solid Dupixent Show
by Zacks Equity Research
Regeneron (REGN) beats on Q4 earnings and sales on solid performance of Dupixent, Eylea and incremental contribution from oncology drug, Libtayo.
Sanofi (SNY) Q4 Earnings & Sales Miss, 2021 EPS View Bright
by Zacks Equity Research
Sanofi's (SNY) Q4 earnings and sales miss estimates. Dupixent drives sales growth in the quarter
Why Earnings Season Could Be Great for Sanofi (SNY)
by Zacks Equity Research
Sanofi (SNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Novo Nordisk's (NVO) Q4 Earnings and Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) beats both earnings and sales estimates for the fourth quarter of 2020.
Will Eylea, Dupixent Drive Regeneron's (REGN) Q4 Earnings?
by Zacks Equity Research
Investors are likely to focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports fourth-quarter 2020 results.
Will Merck (MRK) Keep the Earnings Streak Alive in Q4?
by Zacks Equity Research
Investor focus is likely to be on the sales numbers of Merck's (MRK) blockbuster oncology medicine, Keytruda.
5 Big Pharma/Biotech Stocks Set to Trump Q4 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks including Sanofi (SNY) and Merck (MRK) that are poised to beat fourth-quarter earnings estimates.
Sanofi (SNY) to Manufacture BioNTech's Coronavirus Vaccine
by Zacks Equity Research
Sanofi (SNY) to support manufacturing and supply of BioNTech's COVID-19 vaccine candidate, which the latter has developed in partnership with Pfizer.
Regeneron's (REGN) Performance Strong in 2020: What Lies Ahead?
by Zacks Equity Research
Regeneron's (REGN) efforts to expand the label of its approved drugs and concurrently develop the pipeline are impressive and position it for growth in 2021.
The Zacks Analyst Blog Highlights: Apple, Mastercard, Sanofi, Comcast and Altria Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Mastercard, Sanofi, Comcast and Altria Group
Top Stock Reports for Apple, Mastercard & Sanofi
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Mastercard (MA), and Sanofi (SNY).
Lexicon (LXRX) Soars on FDA Permission for Sotagliflozin NDA
by Zacks Equity Research
Lexicon (LXRX) announces that data from two late-stage studies on its type II diabetes candidate, sotagliflozin, can support a regulatory approval application.
Pharma Stock Roundup: LLY's Alzheimer Disease Data, NVS & SNY's M&A Deals
by Kinjel Shah
Lilly's (LLY) candidate, donanemab shows slowing of cognitive decline in Alzheimer's disease patients. Novartis (NVS) and Sanofi (SNY) announce M&A deals.
Esperion (ESPR) Reports Q4 Preliminary Results, Stock Down
by Zacks Equity Research
Esperion (ESPR) reports fourth-quarter preliminary results and provides guidance for operating expense in 2021. The company in-licenses oral PCSK9 inhibitor program.
Sanofi (SNY) to Acquire Kymab to Boost Immunology Presence
by Zacks Equity Research
Sanofi's (SNY) potential acquisition of Kymab, a private biotech, is set to strengthen its presence in immunology.
Lexicon (LXRX) Starts Dosing in Post-Herpetic Neuralgia Study
by Zacks Equity Research
Lexicon (LXRX) initiates dosing in a mid-stage study on LX9211 for the treatment of post-herpetic neuralgia.
5 Big ETF Stories of 2020 Worth Watching in 2021
by Sweta Killa
We discuss some of the events that dominated the headlines in 2020 and are worth watching in 2021.
Wall Street Stories That Hit Headlines in 2020
by Sweta Killa
With super-easy policies and vaccination, small-cap stocks like Liquidity Services (LQDT) and cyclical stocks like Nexstar Media (NXST), Deere & Company (DE) and BHP Billiton (BBL) are expected to benefit the most.
Evergreen Tree of ETFs to Lighten Your Christmas
by Sweta Killa
The Christmas tree of top-ranked ETFs to brighten 2021 is now ready for investors. May it spread cheer!
U.S. Dollar to Remain Weak in 2021? ETFs to Gain
by Sanghamitra Saha
U.S. dollar is expected to remain weak in 2021, after being beaten down this year.
TIPS ETFs to Buy for 2021 on Inflation Trade
by Sweta Killa
The COVID-19 vaccines and their availability have raised the prospect of inflation as we move ahead into the next year.
The Zacks Analyst Blog Highlights: Facebook, Verizon, Sanofi, QUALCOMM and ICICI Bank
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Verizon, Sanofi, QUALCOMM and ICICI Bank